APPENDICES – Supplementary Reports

Financial Report – September 2012

Table of Contents

Appendix 1 - Summary Financial Performance
Appendix 2 - Financial Risk Rating (FRR)

Appendix 1 – Summary Financial Performance – Income & Expenditure Position

Income & Expenditure Summary September 2012

£000's	Current Period			Year To Date Mth 6			Previous Three Mths Actuals			Forecast Outturn					Prev Mth
	Actual	Plan	Variance	Actual	Plan	Variance	Mth 3	Mth 4	Mth 5	Actual	Plan	Oper Var	BSP Var	Tot Var	Forecast
Revenue															
NHS Clinical Revenue	11,726	11,878	**(152)**	71,996	72,677	**(681)**	11,393	12,480	12,319	145,527	145,021	754	(248)	**506**	145,370
Other Non Clinical Revenue	709	611	**98**	3,904	3,671	**233**	662	608	653	8,111	7,443	592	76	**668**	8,125
Education, Training & Research	472	437	**35**	2,778	2,622	**156**	445	558	437	5,125	5,243	(118)	0	**(118)**	5,104
Sub Total Revenue	**12,907**	**12,926**	**(19)**	**78,678**	**78,970**	**(292)**	**12,500**	**13,646**	**13,409**	**158,763**	**157,707**	**1,228**	**(172)**	**1,056**	**158,599**
Drugs Excluded From Tariff	585	623	**(38)**	3,880	3,750	**130**	629	630	709	7,633	7,506	127	0	**127**	7,677
Total Revenue	**13,492**	**13,549**	**(57)**	**82,558**	**82,720**	**(162)**	**13,129**	**14,276**	**14,118**	**166,396**	**165,213**	**1,355**	**(172)**	**1,183**	**166,276**
Expenditure															
Employee benefit expenses	(9,308)	(9,255)	**(53)**	(56,338)	(56,153)	**(185)**	(9,437)	(9,457)	(9,438)	(111,834)	(111,647)	3,007	(3,194)	**(187)**	(112,539)
Non Pay expenditure	(3,146)	(3,010)	**(136)**	(18,740)	(18,677)	**(63)**	(3,020)	(3,206)	(3,070)	(38,152)	(37,299)	(628)	(225)	**(853)**	(37,922)
Sub Total Expenditure	**(12,454)**	**(12,265)**	**(189)**	**(75,078)**	**(74,830)**	**(248)**	**(12,457)**	**(12,663)**	**(12,508)**	**(149,986)**	**(148,946)**	**2,379**	**(3,419)**	**(1,040)**	**(150,461)**
Drugs Excluded From Tariff	(585)	(623)	**38**	(3,880)	(3,750)	**(130)**	(629)	(630)	(709)	(7,633)	(7,506)	(127)	0	**(127)**	(7,677)
Total Costs	**(13,039)**	**(12,888)**	**(151)**	**(78,958)**	**(78,580)**	**(378)**	**(13,086)**	**(13,293)**	**(13,217)**	**(157,619)**	**(156,452)**	**2,252**	**(3,419)**	**(1,167)**	**(158,138)**
EBITDA	**453**	**661**	**(208)**	**3,600**	**4,140**	**(540)**	**43**	**983**	**901**	**8,777**	**8,761**	**3,607**	**(3,591)**	**16**	**8,138**
Restructuring Costs	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	(800)	0	(800)	0	**(800)**	(800)
Transfer from Donation Reserve	0	34	**(34)**	254	260	**(6)**	35	(1)	160	954	860	94	0	**94**	860
Interest Receivable	3	4	**(1)**	23	21	**2**	6	3	5	41	41	0	0	**0**	41
PDC Dividends Payable	(213)	(176)	**(37)**	(1,078)	(1,054)	**(24)**	(178)	(169)	(164)	(2,150)	(2,108)	(42)	0	**(42)**	(2,108)
Interest Payable	(8)	(20)	**12**	(118)	(124)	**6**	(15)	(46)	(16)	(211)	(249)	38	0	**38**	(249)
Depreciation	(437)	(477)	**40**	(2,600)	(2,660)	**60**	(429)	(438)	(437)	(5,625)	(5,656)	31	0	**31**	(5,656)
Profit or (Loss) on Disposal	0	0	**0**	(1)	0	**(1)**	0	(15)	0	0	0	0	0	**0**	0
Net Surplus	**(202)**	**26**	**(228)**	**80**	**583**	**(503)**	**(538)**	**317**	**449**	986	1,649	2,928	**(3,591)**	**(663)**	**226**
EBITDA Margin	**3.4%**	**4.9%**		**4.4%**	**5.0%**		**0.3%**	**6.9%**	**6.4%**	**5.3%**	**5.3%**				**4.9%**

Appendix 1 (cont.) – Summary Financial Performance – EBITDA Margin %



Appendix 2 – Financial Risk Rating (FRR)

Financial Risk Ratings for September 2012 (month 6)

Criteria	Metric	Weight	5	4	3	2	1	Annual Plan Risk ratings 12/13	Month 6 Score 12/13	Month 6 Risk ratings 12/13	Year to Date Score 12/13	Year to Date Risk ratings 12/13
Underlying performance	EBITDA margin %	25%	11	9	5	1	<1	3	3.4%	2	4.4%	2
Achievement of plan	EBITDA achieved %	10%	100	85	70	50	<50	3	68.5%	2	86.9%	4
Financial efficiency	Net return after financing %	20%	3	2	-1	-5	<-5	3	-3.2%	2	-0.5%	3
	I&E surplus margin %	20%	3	2	1	-2	<-2	3	-1.5%	2	0.1%	2
Liquidity	Liquid ratio days	25%	60	25	15	10	<10	4	26.5	4	26.5	4
Average								3.25		2.50		2.90
Overriding rules	Overriding rules	At least two criteria on 2						No		Yes		No
Overall rating	Overall rating							3		2		3